English (UK)
中文版Biolingus 
BioLingus is an award-winning Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins. Our technology is "inspired by nature" using applied bio-engineering, resulting in novel bio-mimetic materials for drug delivery. Our company focusses on the development of its own products on the treatment of chronic diseases, such as diabetes, obesity and inflammatory diseases.
BioLingus’ main office is in Switzerland, with satellite companies in Hong Kong and Australia.
See also video made by the Swiss Chinese Chamber of Commerce : https://www.linkedin.com/posts/yvesdecadt_icbc-vischer-gunvor-activity-6737745258496434176-8BZc
Yves Decadt
CEOCerevel Therapeutics 
We seek to transform the lives of people suffering from neuroscience diseases, including Parkinson’s disease, epilepsy and schizophrenia, through the development of novel therapies. We have built a highly experienced team of senior leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with the proven expertise of pharmaceutical company drug discovery and development.
Scott Lewis
Corporate Development & StrategyGlenpharma AB 
Glenpharma AB is a small privately owned research spin-off from Pfizer-Pharmacia, formed in Sweden in 2002 to exploit novel technology patented by its founders.
We offer patented synergistic combinations of biopolymers for
a) accelerated repair of acute tendon /ligament injuries in human applications ( such as sprained ligaments / tendons in shoulder, elbow, knee, ankle, etc , in both sports injury scenarios and in the elderly ) , or in veterinary indications (e.g. high performance horses) . The product accelerates healing at least 3 times faster than the normal healing process.
b) for prevention of unwanted adhesions between tissues after major thoracic, abdominal , fertility or orthopedic surgery. In studies on prevention of difficult adhesions after cardiac surgery, for example, adhesion scores were < 10% of those in control groups.
c) for effective control of acute pain in advanced joint disease (osteo-arthritis (OA) . Clinical documentation in advanced OA indicates that onset of pain relief is much faster and of longer duration than current standards for viscosupplementation.
Each of the above biopolymer "viscous fluid implants" are also ideal drug delivery media for treatment of ancillary complications.
All component biopolymers are well documented APIs, i.e. without the toxicty and other regulatory issues generally associated with "New Chemical Entities". Glenpharma´s current patent protection covers most major international markets including USA, Europe and P R China.
Glenpharma is primarily seeking Chinese partners for out-licensing within the fields of orthopedics or major surgery.. If neccessary , we can offer contract-manufacturing options in Europe if not available in China.
Senior Scientist Peter Buckley
CEOGlobal Clinical Trials (GCT)
GCT team, that now consists of over 100 full-time clinical research professionals, gives individualized attention to each project and provides full range of services following the latest GCP, EMA and FDA guidelines at every stage of product development path. Our monitors and project managers are all certified clinicians experienced in GCP clinical research. Our experience, competent staff, close contact with the KOLs and the immense enrollment potential of the covered region ensure fast study start-up and compliance with the set timelines.
GCT owns 400 sq.m. (4300 ft2) Drug Storage and Distribution facility in St. Petersburg, Russia. It is fully equipped, disaster protected and has multiple modes of storage (ambient, climate controlled, refrigerated, frozen). High standards of work and client satisfaction are proved by the fact that more than 80% of the business come from repeat clients.
Since 2006 GCT is also an Exclusive Partner of “The White Nights” International ophthalmology congress in Russia.
Aleksandr Stiblo
Director, Business Development
Jupiter Orphan Therapeutics Inc. (JOT)
Christer Rosen
Chairman & CEO
Regulaxis SAS 
Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.
Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.
Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.
Dr Matthieu CHAREYRE
Chief Business Development Officer - Global Pharmaceutical Operations
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd 
Kelun-Biotech Biopharmaceutical is a subsidiary of Kelun Pharmaceutical Group established in 2016
Looking for antibody and samall molecular out-license and in-license
Responsive Web Design powered by 